Skip to main content
Top
Published in: BMC Geriatrics 1/2021

Open Access 01-12-2021 | Geriatric Cardiology | Research article

Cardiovascular disease and cumulative incidence of cognitive impairment in the Health and Retirement Study

Authors: Allyson L. Covello, Leora I. Horwitz, Shreya Singhal, Caroline S. Blaum, Yi Li, John A. Dodson

Published in: BMC Geriatrics | Issue 1/2021

Login to get access

Abstract

Background

We sought to examine whether people with a diagnosis of cardiovascular disease (CVD) experienced a greater incidence of subsequent cognitive impairment (CI) compared to people without CVD, as suggested by prior studies, using a large longitudinal cohort.

Methods

We employed Health and Retirement Study (HRS) data collected biennially from 1998 to 2014 in 1305 U.S. adults age ≥ 65 newly diagnosed with CVD vs. 2610 age- and gender-matched controls. Diagnosis of CVD was adjudicated with an established HRS methodology and included self-reported coronary heart disease, angina, heart failure, myocardial infarction, or other heart conditions. CI was defined as a score < 11 on the 27-point modified Telephone Interview for Cognitive Status. We examined incidence of CI over an 8-year period using a cumulative incidence function accounting for the competing risk of death.

Results

Mean age at study entry was 73 years, 55% were female, and 13% were non-white. Cognitive impairment developed in 1029 participants over 8 years. The probability of death over the study period was greater in the CVD group (19.8% vs. 13.8%, absolute difference 6.0, 95% confidence interval 2.2 to 9.7%). The cumulative incidence analysis, which adjusted for the competing risk of death, showed no significant difference in likelihood of cognitive impairment between the CVD and control groups (29.7% vs. 30.6%, absolute difference − 0.9, 95% confidence interval − 5.6 to 3.7%). This finding did not change after adjusting for relevant demographic and clinical characteristics using a proportional subdistribution hazard regression model.

Conclusions

Overall, we found no increased risk of subsequent CI among participants with CVD (compared with no CVD), despite previous studies indicating that incident CVD accelerates cognitive decline.
Appendix
Available only for authorised users
Literature
17.
23.
go back to reference Cigolle CT, Nagel CL, Blaum CS, Liang J, Quinones AR. Inconsistency in the self-report of chronic diseases in panel surveys: developing an adjudication method for the health and retirement study. J Gerontol B Psychol Sci Soc Sci. 2018;73:901–12.PubMed Cigolle CT, Nagel CL, Blaum CS, Liang J, Quinones AR. Inconsistency in the self-report of chronic diseases in panel surveys: developing an adjudication method for the health and retirement study. J Gerontol B Psychol Sci Soc Sci. 2018;73:901–12.PubMed
24.
go back to reference Plassman BL, Newman TT, Welsh KA, Helms M, et al. Properties of the telephone interview for cognitive status: Application in epidemiological and longitudinal studies. Neuropsychiatry Neuropsychol Behav Neurol. 1994;7:235–41. Plassman BL, Newman TT, Welsh KA, Helms M, et al. Properties of the telephone interview for cognitive status: Application in epidemiological and longitudinal studies. Neuropsychiatry Neuropsychol Behav Neurol. 1994;7:235–41.
26.
go back to reference Crimmins EM, Kim JK, Langa KM, Weir DR. Assessment of cognition using surveys and neuropsychological assessment: the health and retirement study and the aging, demographics, and memory study. J Gerontol B Psychol Sci Soc Sci. 2011;66(Suppl 1):i162–71.CrossRefPubMed Crimmins EM, Kim JK, Langa KM, Weir DR. Assessment of cognition using surveys and neuropsychological assessment: the health and retirement study and the aging, demographics, and memory study. J Gerontol B Psychol Sci Soc Sci. 2011;66(Suppl 1):i162–71.CrossRefPubMed
27.
go back to reference Langa KM, Weir DR, Kabeto M, Sonnega A. Langa-Weir classification of cognitive function (1995 onward); 2018. Langa KM, Weir DR, Kabeto M, Sonnega A. Langa-Weir classification of cognitive function (1995 onward); 2018.
28.
go back to reference Fisher GG, Hassan H, Faul JD, Rodgers WL, Weir DR. Health and Retirement Study Imputation of Cognitive Functioning Measures: 1992–2014; 2017. Fisher GG, Hassan H, Faul JD, Rodgers WL, Weir DR. Health and Retirement Study Imputation of Cognitive Functioning Measures: 1992–2014; 2017.
31.
go back to reference RStudio Team. RStudio: integrated development for R. Boston: RStudio, PBC; 2020. RStudio Team. RStudio: integrated development for R. Boston: RStudio, PBC; 2020.
32.
go back to reference Gray RJ. Package ‘cmprsk’: subdistribution analysis of competing risks; 2019. Gray RJ. Package ‘cmprsk’: subdistribution analysis of competing risks; 2019.
33.
go back to reference Austin PC. Practical recommendations for reporting Fine - Gray model analyses for competing risk data; 2017. p. 4391–400. Austin PC. Practical recommendations for reporting Fine - Gray model analyses for competing risk data; 2017. p. 4391–400.
Metadata
Title
Cardiovascular disease and cumulative incidence of cognitive impairment in the Health and Retirement Study
Authors
Allyson L. Covello
Leora I. Horwitz
Shreya Singhal
Caroline S. Blaum
Yi Li
John A. Dodson
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2021
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-021-02191-0

Other articles of this Issue 1/2021

BMC Geriatrics 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.